CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of brain tumors.
Protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of brain tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在此,我们提出了一种在原发性、转移性和复发性脑肿瘤的患者来源异种移植模型中,对局部递送CAR-T 细胞进行临床前评估的方案。我们提供了分离外周血单核细胞(PBMCs)、结合局部递送生产CAR-T 细胞,以及涉及CAR-T 细胞的临床前试验设计与分析的说明。此外,我们描述了全面的临床前读出指标和关键终点样本采集的指南。与临床试验程序一致,我们的方案拓宽了可直接临床转化的可用治疗模式。关于本方案使用和执行的完整细节,请参阅Donovan等人1。
Here, we present a protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of primary, metastatic, and recurrent brain tumors.
We provide instructions for isolating peripheral blood mononuclear cells (PBMCs), producing CAR T cells in conjunction with locoregional delivery, and preclinical trial design and analysis involving CAR T cells.
Additionally, we describe comprehensive preclinical readouts and guidelines for critical endpoint sample collections. In line with clinical trial procedures, our protocol broadens available treatment modalities for direct clinical translation. For complete details on the use and execution of this protocol, please refer to Donovan et al. 1 .
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。